Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/30/2026

1. META
2. MSFT
3. FTNT
4. QCOM
5. ARM
6. SBUX
7. TENB
8. CMG
9. SPY
10. CVNA

Go back to Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
(NASDAQ: ABSI) Delayed: 6.90 --0 (-0%)
Previous Close $6.90    52 Week High $ 
Open $6.90    52 Week Low $ 
Day High $6.90    P/E N/A 
Day Low $6.90    EPS $ 
Volume 15,313